Log in

ETR:EVTEvotec Stock Price, Forecast & News

€23.73
-0.19 (-0.79 %)
(As of 07/13/2020 03:46 AM ET)
Add
Compare
Today's Range
€23.61
Now: €23.73
€23.96
50-Day Range
€23.18
MA: €24.16
€25.33
52-Week Range
€17.17
Now: €23.73
€27.29
Volume411,145 shs
Average Volume1.36 million shs
Market Capitalization$3.59 billion
P/E Ratio87.89
Dividend YieldN/A
BetaN/A
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. The EVT Innovate segment is involved in investing and developing proprietary assets, including early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; and drug discovery alliance with LEO Pharma. The company was founded in 1993 and is headquartered in Hamburg, Germany.
Read More
Evotec logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-40-560810

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$461.99 million
Cash Flow€2.08 per share
Book Value€3.24 per share

Profitability

Miscellaneous

Employees2,617
Market Cap$3.59 billion
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive EVT News and Ratings via Email

Sign-up to receive the latest news and ratings for EVT and its competitors with MarketBeat's FREE daily newsletter.

Evotec (ETR:EVT) Frequently Asked Questions

How has Evotec's stock been impacted by COVID-19 (Coronavirus)?

Evotec's stock was trading at €20.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EVT stock has increased by 14.1% and is now trading at €23.73. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Evotec?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evotec.

When is Evotec's next earnings date?

Evotec is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Evotec.

What price target have analysts set for EVT?

3 brokers have issued 12-month price targets for Evotec's stock. Their forecasts range from €28.00 to €33.00. On average, they expect Evotec's stock price to reach €29.67 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price. View analysts' price targets for Evotec.

Has Evotec been receiving favorable news coverage?

Headlines about EVT stock have been trending very negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evotec earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Evotec.

Who are some of Evotec's key competitors?

What other stocks do shareholders of Evotec own?

Who are Evotec's key executives?

Evotec's management team includes the following people:
  • Dr. Werner Lanthaler, CEO & Member of Management Board (Age 51)
  • Mr. Enno Spillner, CFO & Member of Management Board (Age 49)
  • Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 55)
  • Dr. Craig Johnstone, COO & Member of Management Board
  • Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting

What is Evotec's stock symbol?

Evotec trades on the ETR under the ticker symbol "EVT."

What is Evotec's stock price today?

One share of EVT stock can currently be purchased for approximately €23.73.

How big of a company is Evotec?

Evotec has a market capitalization of $3.59 billion and generates $461.99 million in revenue each year. Evotec employs 2,617 workers across the globe.

What is Evotec's official website?

The official website for Evotec is www.evotec.com.

How can I contact Evotec?

Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The company can be reached via phone at +49-40-560810.

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.